You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 277 No. 13, April 2, 1997 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contributions
 This Article
 •References
 •Full text PDF
 •Correction
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Efficacy of Midodrine vs Placebo in Neurogenic Orthostatic Hypotension

A Randomized, Double-blind Multicenter Study

Phillip A. Low, MD; Janice L. Gilden, MD; Roy Freeman, MD; Ke-Ning Sheng, PhD; Mary Ann McElligott, PhD

JAMA. 1997;277(13):1046-1051.


Abstract

Objective.
—To evaluate the efficacy of a 10-mg dose of midodrine 3 times per day in improving blood pressure (BP) and ameliorating symptoms of orthostatic hypotension in patients with neurogenic orthostatic hypotension. Midodrine hydrochloride, an {alpha}=agonist, could improve orthostatic BP by increasing vasomotor and venomotor tone.

Design/Methods.
—A total of 171 patients with orthostatic hypotension participated in a multicenter, randomized, placebo-controlled study. They were randomized to a 10-mg dose of midodrine or placebo 3 times per day in a 6-week study, comprising single-blind run-in (at week 1) and washout at weeks 5 and 6, with an intervening double-blind period (weeks 2 to 4).

Setting.
—Twenty-five centers, with most patients evaluated in referral centers.

Main Outcome Measures.
—The primary end points were improvement in standing systolic BP, symptoms of lightheadedness, and a global symptom relief score (by the investigator and patient separately).

Results.
—Nine patients were not evaluable because of noncompliance or taking concomitant vasoactive medications (3 in the midodrine group, 6 in the placebo group). In the evaluable patients, midodrine resulted in improvements in standing systolic BP at all time points (P<.001 at visits 2,3,4, and 5), in reported symptoms by the end of the second week of treatment (P=.001), and in the global symptom relief score rated by both the patient (P=.03) and the investigator (P<.001). There was no effect by center, severity of orthostatic hypotension, use of fludrocortisone or compression garments, or diagnosis. The main adverse effects were those of pilomotor reactions, urinary retention, and supine hypertension.

Conclusions.
—Midodrine is efficacious and safe in the treatment of neurogenic orthostatic hypotension.



Author Affiliations

for the Midodrine Study Group

From the Department of Neurology, Mayo Clinic, Rochester, Minn (Dr Low); Finch University of Health Sciences, The Chicago Medical School, North Chicago, III (Dr Gilden); Beth Israel-Deaconess Medical Center, Boston, Mass (Dr Freeman); and Roberts Pharmaceutical Corp, Eatontown, NJ (Drs Sheng and McElligott).


Footnotes

A complete list of the Midodrine Study Group appears at the end of this article.

Nothing in this publication implies that Mayo Foundation endorses the products of Roberts Pharmaceutical Corp.

Reprints: Phillip A. Low, MD, Autonomic Reflex Laboratory, Department of Neurology, Mayo Clinic, 811 Guggenheim Bldg, Rochester, MN 55905 (e-mail: low.phillip@mayo.edu).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC)
Developed in collaboration with et al.
Eur Heart J 2009;30:2631-2671.
FULL TEXT  

Invited Article: Autonomic ganglia: Target and novel therapeutic tool
Vernino et al.
Neurology 2008;70:1926-1932.
ABSTRACT | FULL TEXT  

Neurogenic Orthostatic Hypotension
Freeman
NEJM 2008;358:615-624.
FULL TEXT  

Pharmacokinetics of Pyridostigmine in a Child With Postural Tachycardia Syndrome
Filler et al.
Pediatrics 2006;118:e1563-e1568.
ABSTRACT | FULL TEXT  

Pyridostigmine Treatment Trial in Neurogenic Orthostatic Hypotension
Singer et al.
Arch Neurol 2006;63:513-518.
ABSTRACT | FULL TEXT  

The patient with supine hypertension and orthostatic hypotension: a clinical dilemma.
Naschitz et al.
Postgrad. Med. J. 2006;82:246-253.
ABSTRACT | FULL TEXT  

Neurocardiogenic Syncope
Grubb
NEJM 2005;352:1004-1010.
FULL TEXT  

Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure
Schrage et al.
J. Appl. Physiol. 2004;97:1978-1984.
ABSTRACT | FULL TEXT  

A patient with recurrent syncope
Postgrad. Med. J. 2004;80:120-121.
FULL TEXT  

Acetylcholinesterase inhibition in the treatment of hypotension
Schondorf
J. Neurol. Neurosurg. Psychiatry 2003;74:1187-1187.
FULL TEXT  

Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension
Singer et al.
J. Neurol. Neurosurg. Psychiatry 2003;74:1294-1298.
ABSTRACT | FULL TEXT  

Autonomic diseases: management
Mathias
J. Neurol. Neurosurg. Psychiatry 2003;74:iii42-47.
FULL TEXT  

Norepinephrine Precursor Therapy in Neurogenic Orthostatic Hypotension
Kaufmann et al.
Circulation 2003;108:724-728.
ABSTRACT | FULL TEXT  

Supine Hypertension During General Anesthesia in a Patient Taking Midodrine
Chaimberg and Travis
Anesth. Analg. 2002;95:1196-1197.
ABSTRACT | FULL TEXT  

Levodopa strengths and weaknesses
Jankovic
Neurology 2002;58:S19-32.
ABSTRACT | FULL TEXT  

Amyloidosis
Khan and Falk
Postgrad. Med. J. 2001;77:686-693.
ABSTRACT | FULL TEXT  

Normalization of Blood Pressure in a Patient With Severe Orthostatic Hypotension and Supine Hypertension Using Clonidine
Brahmbhatt et al.
Hypertension 2001;37 :e24-e24.
FULL TEXT  

Ambulatory norepinephrine treatment of severe autonomic orthostatic hypotension
Oldenburg et al.
J Am Coll Cardiol 2001;37:219-223.
ABSTRACT | FULL TEXT  

Variability of Blood Pressure Response to Orthostatism and Reproducibility of the Diagnosis of Orthostatic Hypotension in Elderly Subjects
Belmin et al.
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2000;55:667M-671.
ABSTRACT | FULL TEXT  

Diagnostic Yield and Development of a Neurocardiovascular Investigation Unit for Older Adults in a District Hospital
Allcock and O'Shea
Journals of Gerontology Series A: Biological Sciences and Medical Sciences 2000;55:458M-462.
ABSTRACT | FULL TEXT  

New classification of haemodynamics of vasovagal syncope: beyond the VASIS classification: Analysis of the pre-syncopal phase of the tilt test without and with nitroglycerin challenge
Brignole et al.
Europace 2000;2:66-76.
ABSTRACT  

The treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine: A randomized, placebo-controlled, crossover trial
Freeman et al.
Neurology 1999;53:2151-2151.
ABSTRACT | FULL TEXT  

Treatment of postural hypotension
MATHIAS and KIMBER
J. Neurol. Neurosurg. Psychiatry 1998;65:285-289.
FULL TEXT  

Treatment of Orthostatic Hypotension with Midodrine and Octreotide
Hoeldtke et al.
J. Clin. Endocrinol. Metab. 1998;83:339-343.
ABSTRACT | FULL TEXT  

Efficacy of Midodrine for Neurogenic Orthostatic Hypotension
Berlin
JAMA 1997;278:388-388.
ABSTRACT  

MIDODRINE EFFECTIVE FOR NEUROGENIC ORTHOSTATIC HYPOTENSION.
JWatch General 1997;1997:2-2.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1997 American Medical Association. All Rights Reserved.